Organogenesis Holdings Inc. (ORGO) News
Follow Organogenesis Holdings Inc. (ORGO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Organogenesis Reports Q3 Revenue of $45.5 Million, Cuts 2026 Guidance
Organogenesis reported a $29.6 million net loss, or $0.25 per share, versus net income of $21.6 million a year earlier. It lowered full-year 2026 revenue guidance to $179 million–$200 million. The FDA’s pre-license inspe
EQUITY | Nov 06, 2026, 02:05 PM UTC
M
Organogenesis Holdings Reports Third-Quarter Loss per Share
EQUITY | Nov 05, 2026, 09:18 PM UTC
M
Organogenesis Reports Third-Quarter 2026 Financial Results
EQUITY | Nov 05, 2026, 09:08 PM UTC
M
Organogenesis to report fiscal Q3 2026 results November 5
Organogenesis Holdings Inc. said it will report third-quarter fiscal 2026 financial results on November 5, 2026.
EQUITY | Oct 12, 2026, 08:05 PM UTC
H
Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq 100 futures gaining over 100 points on Friday. Shares of Trade Desk Inc (NASDAQ: TTD ) fell sharply in pre-market trading after the company reported worse-than-
EARNINGS | Aug 07, 2026, 12:02 PM UTC
H
Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket
Shares of Atlassian Corp (NASDAQ: TEAM ) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results. Atlassian reported fourth-quarter revenue of $1.766 billion, u
EARNINGS | Aug 07, 2026, 08:33 AM UTC
L
Organogenesis Holdings Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $179.000M-$215.000M vs $282.850M Est
Organogenesis Holdings (NASDAQ: ORGO ) lowers FY2026 sales outlook from $270.000 million-$310.000 million to $179.000 million-$215.000 million vs $282.850 million estimate.
EARNINGS | Aug 06, 2026, 08:16 PM UTC
L
ORGO Organogenesis announces publication of peer-reviewed clinical trial results demonstrating clinical benefit of affinity™ in the most cha
ORGO Organogenesis announces publication of peer-reviewed clinical trial results demonstrating clinical benefit of affinity™ in the most challenging and complex venous leg ulcers
EQUITY | Jul 27, 2026, 08:05 PM UTC
H
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday. Shares of Danaher Corp (NYSE: DHR ) fell sharply in pre-market trading following second-quarter results. Danaher p
EARNINGS | Jul 21, 2026, 12:01 PM UTC
L
Organogenesis announces FDA acceptance of ReNu biologics license application
Organogenesis announced that the FDA has completed their filing determination and accepted for review the company's biologics license application, or BLA, for ReNu, a cryopreserved, amniotic suspension allograft develope
EQUITY | Jul 06, 2026, 08:08 PM UTC